About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Non-Hodgkin Lymphoma in Older Patients: Need to Identify Fit Patients w/ Aggressive Disease to Receive Full Standard Dose at 1st Line (R-CHOP / R-miniCHOP)
By
19th Conference of the International Society of Geriatric Oncology
FEATURING
Raul Cordoba
By
19th Conference of the International Society of Geriatric Oncology
FEATURING
Raul Cordoba
34 views
December 31, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
18:26
William Schaffner
Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024
New Updates in Frontline DLCBL
Feat.
L. Nastoupil
62:02
UChicago Medicine
New Treatment Strategies in DLBCL
Feat.
L. Sehn
17:21
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…
15:33
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…
Feat.
J. Friedberg
25:44
Tara Graff
DLBCL Updates From iCML 2023
06:09
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…
Feat.
A. Kittai
35:28
UNC Lineberger Comprehensive Cancer Center
DLBCL Management: Updates for 2023
Feat.
N. Grover
17:11
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Incorporating Novel Agents in Frontline DLBCL
Feat.
L. Sehn
16:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas
Feat.
D. Landsburg
26:58
Total Health
Update on Cellular Therapy in Lymphoma
Feat.
B. Randolph
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
15:31
SOHO 2022 Tenth Annual Meeting
SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?
Feat.
L. Sehn
13:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitama…
Feat.
J. Westin
47:35
University of Colorado Division of Hematology
Overview of DLBCL: Diagnosis to Treatment
Feat.
E. Fahey-Harrison
35:24
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Aggressive B-Cell Lymphomas
Feat.
G. Nowakowski
02:53
PrecisCa
The POLARIX Trial: Polatuzumab With R-CHP in DLBCL
Feat.
M. Kamdar
33:36
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: Cell Therapy
Feat.
M. de Lima
